Venus MedTech (HKEX: 2500) is a leading Chinese structural heart company developing transcatheter heart valve technologies. Its product portfolio includes VenusP-Valve (transcatheter pulmonary valve), Venus-A (TAVR), and the Venus-PowerX system (first fully recoverable self-expanding dry-valve TAVR).
Company Info
Recent News
Venus Medtech annonce la fin du recrutement des patients pour l'essai clinique chinois de Venus Powerx.
Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World's First Fully Recoverable Self-Expanding Dry-Valve TAVR System.
Venus Medtech ha finalizado el reclutamiento de pacientes para el ensayo clínico de Venus Powerx TAVR en China.
Venus Medtech hat den Abschluss der Patientenrekrutierung für die entscheidende chinesische Studie zu Venus Powerx bekannt gegeben.
Leadership Team
Careers & Job Openings